Emulate - About the company
Emulate is a series E company based in Boston (United States), founded in 2013. It operates as a Developer of in vitro models for drug development. Emulate has raised $204M in funding from investors like OS Fund, ALS and ND Capital, with a current valuation of $*****. The company has 49 active competitors, including 21 funded and 2 that have exited. Its top competitors include companies like Mimetas, CN Bio and Hesperos.
Company Details
Developer of in vitro models for drug development. The company has culture modules, organ-chips, and analytical software applications. The proprietary Organ-Chip models including the liver, intestine, kidney, and others contain tiny hollow channels lined with tens of thousands of living human cells and tissues are designed to predict human response.
- Website
- emulatebio.com
- Email ID
- *****@emulatebio.com
- Phone Number
- +1 **********
- Registered Address
- Boston, Massachusetts
Key Metrics
Founded Year
2013
Location
Boston, United States
Stage
Series E
Total Funding
$204M in 10 rounds
Latest Funding Round
Post Money Valuation
$***** as on Sep 17, 2026
Ranked
2nd among 49 active competitors
Employee Count
72 as on Oct 31, 2026
Legal entities associated with Emulate
Emulate is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
EMULATE GERMANY CIN: 0805.535.609 , Belgium, Active | Sep 01, 2023 | - | - | - |
Emulate Inc. CIN: 464857430 , United States, Active | Dec 31, 2012 | - | 93 (As on Dec 31, 2024) | - |
Sign up to download Emulate's company profile
Emulate's funding and investors
Emulate has raised a total funding of $204M over 10 rounds. Its first funding round was on Jul 28, 2014. Its latest funding round was a Grant (prize money) round on Sep 23, 2025 for $*****. 1 investor participated in its latest round. Emulate has 26 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Emulate:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 23, 2025 | 8702770 | Grant (prize money) | 7281581 | 4116909 | 3806993 | 9690689 |
Sep 07, 2021 | 2240952 | Series E | 5723441 | 3006409 | 9543559 | 8471959 |
Mar 23, 2020 | 8136182 | Conventional Debt | 1874898 | 5430210 | 5362786 | 2718108 |
View details of Emulate's funding rounds and investors
Emulate's founders and board of directors
Founder? Claim ProfileEmulate's Board of Directors
Emulate's board has 24 active members. Aaron Vandevender, James Corbett, Sharon Kedar, Larry Weiss, Donald Ingber, Martin Madaus, Andrew Stevenson, Eric Moessinger, Shlomo Melmed, Franklin R. Witney, Michael Egholm, Franklin Witney, Scott Kantor, Harminder Dhaliwal, Gregory D. Williams, James David Coon, Geraldine Hamilton, Sandy Lazzari, Daniel Levner, Lewis Rowe, Hansjoerg Wyss, Monique Noel, David James Coon and Geraldine A. Hamilton are independent board members.Here is the list of Emulate's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Independent board member | - | Current | 8y 2m | |
zgiy{mb | Independent board member | - | Current | 2y 9m |
vbmnhkj | Independent board member | - | Current | 5y 9m |
deqneyi | Independent board member | - | Current | 6y 7m |
vgciket | Independent board member | - | Current | 8y 9m |
vgvoydt | Independent board member | - | Current | 7y 5m |
dcftsoh | Independent board member | - | Current | 9y 5m |
kxbndzv | Independent board member | - | Current | 3y 4m |
uzmowoj | Independent board member | - | Current | 7y 6m |
lxrgi{g | Independent board member | - | Current | 1y 4m |
drtydjk | Independent board member | - | Current | 9y 5m |
aztreof | Independent board member | - | Current | 3y 7m |
lsmnqzb | Independent board member | - | Current | 4y 9m |
swzinvk | Independent board member | - | Current | 2y 8m |
npkzqsd | Independent board member | - | Current | 8y 8m |
wcktdtv | Independent board member | - | Current | 5y 5m |
krhxxtq | Independent board member | - | Current | 5y 5m |
xolxijj | Independent board member | - | Current | 2y 2m |
hefyamq | Independent board member | - | Current | 7y 7m |
rujxxhu | Independent board member | - | Current | 3y 7m |
klphjfn | Independent board member | - | Current | 4y 3m |
bswed{u | Independent board member | - | Current | 7y 3m |
ritnsst | Independent board member | - | Current | 7y 5m |
itpgtio | Independent board member | - | Current | 5y 1m |
Emulate's employee count trend
Emulate has 72 employees as of Oct 26. Here is Emulate's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Emulate's Competitors and alternates
Top competitors of Emulate include Mimetas, CN Bio and Hesperos. Here is the list of Top 10 competitors of Emulate, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Mimetas 2013, Leiden (Netherlands), Acquired | Develops microfluidics-based organ-on-a-chip tissue models | $28.9M | 60/100 | |
2nd | Emulate 2013, Boston (United States), Series E | Developer of in vitro models for drug development | $204M | 55/100 | |
3rd | CN Bio 2009, Cambridge (United Kingdom), Series B | Develops organ-on-a-chip platforms for drug discovery | $71.2M | 58/100 | |
4th | Hesperos 2015, Orlando (United States), Funding Raised | Developer of organ-on-a-chip solutions for preclinical testing | - | 53/100 | |
5th | Obatala Sciences 2017, New Orleans (United States), Series A | Provider of research enabling products and services to research centers | $3.54M | 44/100 | |
6th | Numa Biosciences 2007, Woodinville (United States), Acquired | Developer of platform for generating small segments of human tissues and organs in microfluidic chips | $10.7M | 43/100 | |
7th | Developer of a device for in vitro cancer testing using a microfluidic chip | $11.2M | 42/100 | ||
8th | Vivodyne 2021, Philadelphia (United States), Series A | Developer of AI-based platform for lab-grown human tissues | $80M | 41/100 | |
9th | AxoSim 2014, New Orleans (United States), Series A | Engineering human brain and nerve models for neurological insights | $6.78M | 40/100 | |
10th | Mepsgen 2019, Seoul (South Korea), Series C | Developer of human organ model chips for pharmaceutical development | $29.3M | 40/100 |
Looking for more details on Emulate's competitors? Click here to see the top ones
Emulate's Investments and acquisitions
Emulate has made no investments or acquisitions yet.
Reports related to Emulate
Here is the latest report on Emulate's sector:
News related to Emulate
Media has covered Emulate for a total of 3 events in the last 1 year, 1 of them has been about partnerships.
•
•
•
EMulate Therapeutics Opens Community Investment Round on Wefunder, Offering Public AccessBakersfield•Oct 28, 2025•Wefunder, Emulate
•
Emulate Launches AVA Emulation System to Boost Drug DevelopmentWorld Business Outlook•Jun 10, 2025•Emulate
•
•
Emulate Earns Frost & Sullivan's 2023 Technology Innovation Leadership AwardPR Newswire•Oct 12, 2023•Emulate
•
Emulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics MarketsBusiness Wire•Jun 26, 2023•Emulate
•
Emulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023Tullahoma News•Mar 02, 2023•Emulate
•
•
Are you a Founder ?
FAQs about Emulate
Explore our recently published companies
- Alliance Group - 1973 founded, Unfunded company
- jimpeet.co - United Kingdom based, Unfunded company
- Eva Mitic - Victoria based, Unfunded company
- Zutual AI - India based, 2024 founded, Unfunded company
- Whitecap Linen - United States based, 1999 founded, Unfunded company
- ABM Grup - Turkey based, Unfunded company